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We describe the eﬀect on the neonate of administration of rituximab to a woman with idiopathic thrombocytopenic purpura
(ITP). Rituximab, an anti-CD20 antibody, was given weekly for 4 weeks to a woman with ITP in her third trimester of pregnancy.
One month after the last rituximab administration a healthy girl was born. She had normal growth and development during the
first six months. At birth, B-lymphocytes were not detectable. Rituximab levels in mother and neonate were 24000 and 6700 ng/mL,
respectively. Only 7 cases of rituximab administration during pregnancy were described. No adverse events are described for fetus
and neonate. We demonstrate that rituximab passes the placenta and inhibits neonatal B-lymphocyte development. However,
after 6 months B-lymphocyte levels normalized and vaccination titres after 10 months were adequate. No infection-related
complications occurred. Rituximab administration during pregnancy appears to be safe for the child but further studies are
warranted.
Copyright © 2008 D. T. Klink et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Management of a pregnant patient with immune-mediated
thrombocytopenia (ITP) is similar to that of nonpregnant
patients [1]. Corticosteroids are very eﬃcient and inexpen-
sive and commonly used for this indication [2]. Although
considered generally safe, steroids have been reported to have
adverse eﬀects, including oral clefts and osteoporosis [3].
Intravenous immunoglobulins (IVIGs) are a good alterna-
tive. In case of refractory ITP in pregnant patients, a com-
bination of corticosteroids and IVIG can be given. Similar
to nonpregnant patients, a splenectomy can be considered.
Remission of ITP is achieved in 70% of pregnant women
after splenectomy [4]. When splenectomy is considered it
should be performed in the second trimester of pregnancy.
The aim of treatment of ITP in pregnancy is adequate platelet
count to reduce the risk of hemorrhage during labour. Both
mother and neonate are at risk for severe bleeding as low-
neonatal platelet count occurs in 20–25% of the oﬀspring of
ITP patients [5]. When conventional therapy fails, treatment
with third- and fourth-line medications for refractory ITP is
indicated. Unfortunately, their safety during pregnancy has
not been established. For example, azathioprine is associated
with intrauterine growth retardation and immunosupression
[6, 7], and medications such as danazol and vincristin should
be avoided due to their teratogenicity [8]. In order to provide
safe alternatives during pregnancy, novel treatment strategies
are under investigation for the management of ITP. These
innovative approaches include thrombopoietin, anti-CD40
ligand, and rituximab, a monoclonal anti-CD20 antibody
[1].
Rituximab is a chimeric human and murine mono-
clonal antibody and targets the CD20 antigen expressed
on pre-B cells and mature B-lymphocytes [9]. Rituximab-
opsonized B-cells are destroyed by at least three pathways:
lysis through complement-mediated cytotoxicity, opsonic
phagocytosis, and natural killer cell-mediated cytotoxic-
ity [10]. The antibody was originally developed for the
treatment of B-cell lymphoma [11]. Recently, however,
the use of rituximab is expanded to the treatment of
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diﬀerent autoimmune diseases including ITP [12]. The
number of (autoreactive) B-cells is diminished in patients
treated with rituximab. Since rituximab is an IgG-based
antibody, it may cross the placenta and then inter-
fere with fetal and neonatal B-cell development, poten-
tially leading to immune deficiency and increased sus-
ceptibility to infections in the neonate. However, few
data are available on the use of rituximab during preg-
nancy.
We present a case report on the eﬀects of rituximab
on a child after exposure during third trimester preg-
nancy. In addition, we performed a literature search for
additional data in order to gain more insight on the
safety aspects of rituximab administration during preg-
nancy.
Case
A 36-year-old woman was diagnosed with ITP since 1994.
At that time during pregnancy, ITP was successfully treated
with corticosteroids. In 1997, a splenectomy was performed.
During present pregnancy, she was initially treated with
corticosteroids and IVIG, but the platelet count only rose
from 16 × 109/L to 27 × 109/L with persisting hemorrhagic
diathesis.Subsequently, she was referred to our hospital and
treated for refractory ITP with 60 mg prednisone daily.
This treatment was continued during pregnancy until two
weeks prior to delivery. In addition, from week 30 to week
34, she also received rituximab 375 mg/m2 intravenously
weekly for 4 consecutive weeks. Due to persisting low-
platelet count, rituximab administration was ceased and
IVIG administration was started for two consecutive days
at 37 weeks and 6 days of gestation. At 38 weeks and 2
days of gestation and one month after the last rituximab
administration, labour was induced with prostaglandins.
For comfort, the mother received promethazine orally and
pethidine intravenously until one hour before birth. A
slightly depressed girl was born with apgar scores of 7, 8,
and 8 at 1, 5, and 10 minutes, respectively. Birth weight was
3780 grams (90th–95th percentile weight for gestational age
according to Kloosterman [13]), length was 46 centimetre
(cm) (third percentile length for gestational age [14]),
and head circumference was 36 cm (98th percentile head
circumference for gestational age [14]). Physical examination
revealed no abnormalities. Cord blood samples were taken
for blood gas analyses and measurement of thrombocytes,
lymphocyte characterization, and rituximab levels. Because
of the administration of opiates intravenously prior to birth,
the slightly depressed neonate was subsequently admitted
to the high-care facility of our neonatology department for
observation. In the next 24 hours, she quickly recovered
spontaneously and no adverse events occurred. The patient
was transferred to the maternity ward and discharged on the
fourth day after birth. She was followed up in the outpatient
clinic for pediatric infectious diseases and immunology of
our hospital. Up to the age of 10 months, she developed
normally, and growth was not impaired. She did not
have any infectious complications. Vaccination titres were
normal.
2. METHODS
2.1. Rituximab serum level measurement
The rituximab serum levels in cord blood were measured
using enzyme-linked immunosorbent assay (ELISA) at
Xendo Drug Development, Groningen, The Netherlands.
Coeﬃcient of variation was between 4.7% and 8.2%.
2.2. Flow cytometry
Lymphocyte characterization was performed at the Depart-
ment of Pathology. For this purpose, whole blood was
incubated in Trucount tubes with fluorochrome-conjugated
monoclonal antibodies directed against lymphocyte asso-
ciated markers CD3, CD4, CD8, CD16/56, CD19, CD20,
CD27, and CD45 (BD Biosciences, San Jose CA). After
red cell lysis, lymphocyte subsets were analyzed by multi-
parameter flow cytometry (FACSCalibur, BD Biosciences).
B-lymphocytes were quantified as the fraction of CD19
positive cells within the CD45 positive total lymphocyte
gate. B-lymphocyte maturation and memory formation were
analyzed as the percentage of CD19 and CD20 positive, and
CD19 and CD27 positive cells within the total lymphocyte
gate, respectively.
2.3. Review of the literature
Two Embase.com searches were performed on May 1,
2007, with EMTree-terms: (1) (“rituximab”/exp/dd ae
(adverse drug reaction), dd it (drug interaction), dd to
(drug toxicity) AND (“newborn”/exp OR “infant”/exp
OR “fetus”/exp OR “embryo”/exp OR “pregnancy”/exp))
which resulted in 19 references; (2) (“rituximab”/exp AND
“pregnancy”/exp)—54 references. Duplicate references from
both searches were removed, resulting in 42 references. Titles
and abstracts identified were examined to select potentially
relevant studies. In addition, reference lists of identified
studies and review articles were examined.
3. RESULTS OF REPORTED CASE AND
LITERATURE SEARCH
Our literature search resulted in 7 additional case reports on
rituximab use during pregnancy. The relevant data of 8 cases,
including our case, are summarized in Table 1.
3.1. Rituximab levels and B-lymphocytes in the mother
In the majority of the cases, the indication for rituximab was
the presence of a B-cell malignancy. In 3 cases, including
our case, the indication was a haematological disorder which
involved the immune system. Regardless of the indication,
the dosage was the same in all cases with a frequency of
either once a week or every 14 days. Repetition of dosage
was either 4 or 6 times. In combination with nonalkylating
chemotherapy (CHOP), rituximab was eﬀective in reducing
tumorload in 5 cases (Table 1). In 2 cases [15, 16] and our
case, maternal B-cell numbers were determined at the day
of birth and were not detectable. Decker et al. [15] reported
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Table 1: Summary literature search.
Mother
Herold
2001
Kimby
2004
Friedrichs
2006
Scully M
2006
Ojeda-Uribe
2006
Magloire
2006
Decker
2006
Current
study
Condition
B-cell
lymphoma
NH-
lymphoma
Burkitt
lymphoma
Thrombotic
Thrombocy-
topenic
Purpura
Autoimmune
Haemolytic
anaemia
Burkitt
lymphoma
B-cell-NH
lymphoma
ITP
Rituximab
375 mg/m2
Weekly 4x Weekly 4x Weekly 4x Weekly 4x — —
Biweekly
6x
Weekly 4X
Co medication CHOP(1) — CHOP
Plasma
exchange
Corticosteroids CHOP CHOP
Prednisone,
IgG
Administration
time GA
Week 21
Week -1 to
3
Weeks
16–30
Week 27 Week 10
Week 13 to
?
Weeks
16-28
Week 30 to
34
Rituximab level
D0(2)(ng/mL)
— — 9750 — — — 25000 24000
CD19+ B-cells
D0 (1 × 109/L) — — 0 — — — 0 0
Child — — — — — — — —
GA (weeks) 35 40 41 30 38 39 33 38
Rituximab level
D0 (ng/mL)
— — 32095 — — — 30000 6700
CD19+ B-cells
(1 × 109/L) <
week 1 post
partum
— 0,1 0 — 0,66 —
approx
0,05
0,08
CD19+ B-cells
(1 × 109/L) 1
month
normal — — — 1,98 — — 0,00
CD19+ B-cells
(1 × 109/L) 3
months
— — — — — — — 0,21
CD19+ B-cells
(1 × 109/L) 6
months
— — — — — — — 2
Vaccination
titres
— Normal Normal — — — Normal normal
IgA; IgM; IgG
(g/L) 1-2
months
— — — — 0,07; 0,3; 4,5- — —
<0,07; 0,05;
6,1
IgA; IgM; IgG
(g/L) 3 months
— — — — — — —
<0,07;
<0,04; 2,8
IgA; IgM; IgG
(g/L) ≥6
months
—
IgG
normal
Normal — — — Normal
0,16; 0,53;
2,2
(1) Cyclophosphamid, doxorubicin, vincristin, prednisolon.
(2) Day of birth.
a reconstitution of maternal B-cells 12 weeks after delivery
coinciding with a large decrease in serum concentration
of rituximab. At birth, the maternal rituximab levels were
reported to be approximately 25 mg/L when administrated
a month prior to delivery. We have found equal rituximab
levels in our case. Friedrichs et al. [16] reported a lower
level of 9.7 mg/L, but in this case, report rituximab was
administrated around 12 weeks prior to delivery. When
followed up, the rituximab levels decreased corresponding
with its known half-life time [15, 16].
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Figure 1: Flow cytometric analysis of peripheral blood lymphocytes, taken from the neonate at the age of six months, indicating the presence
of CD19 positive B-lymphocytes (20% on average; (a) and (b)), expressing the maturation marker CD20 (99%; (a), and partly expressing
the memory marker CD27 (7%; (b). Analysis was done within the CD45 positive total lymphocyte gate.
3.2. Rituximab levels and B-lymphocytes
in the neonate
At birth, the neonatal rituximab level in our case was
6.7 mg/L. Two other authors reported neonatal rituximab
levels at birth: Friedrichs et al., and Decker et al. reported
a level of 32 mg/L and 30 mg/L, respectively. Both authors
reported a decline in rituximab levels consistent with the
known half-life time of rituximab.
In 2 cases [15, 16] and our case, the number of neonatal
B-cells at time of delivery was determined and was unde-
tectable by flow cytometry. Time of rituximab adminis-
tration during gestation did not appear to influence this
outcome. In our case, the number of B-lymphocytes demon-
strated a steady increase over time. Although the number of
B-cells was still zero 3 weeks after birth, a rise was detected
after 3 months. At the age of 6 months, the number of
B-cells was in the normal range both in absolute and in
relative numbers. Moreover, at this time, all peripheral B-
cells were mature as indicated by CD20 positivity, and B-
cell memory formation could be demonstrated by CD27
positivity (Figure 1). In addition, normal immunoglobulin
(IgG) levels could be demonstrated which is consistent with
findings in other case reports. In our case and in 3 other
cases, [15–17] normal vaccination responses were found.
3.3. Clinical outcome of the neonate
During pregnancy, fetal growth and development were
monitored and turned out to be normal. Indeed, in our case,
the patient’s birth weight was between the 90th and 95th
percentile [13], within the normal range of birth weight in
the Dutch population (outer limit is 97th percentile).
Five out of eight neonates were born at term age
(Table 1). Of the three preterm neonates, one was delivered
by caesarean section due to deterioration of the maternal
condition [18]. No apparent cause for the preterm birth
was reported in the other two neonates. Only one neonate
[19] was described to have been treated with antibiotics
for suspicion of perinatal infection. All other children did
not have any complications in the neonatal period. More
importantly, no single adverse event occurred.
In our case, the neonate was admitted to the high-care
facility for observation due to maternal intravenously opiates
administration. The arterial umbilical cord blood gas anal-
ysis was pH 7.26, CO2 57.0 mmHg, 25.0 HCO3
− mmol/L,
and base excess −3.1 mmol/L, indicating little intrauterine
hypoxic stress. Although our patient was slightly depressed at
birth, she quickly recovered. Thus, the need for further blood
gas analysis was eliminated.
All the children had normal growth and development.
No clinical signs of impaired immunity were observed.
4. DISCUSSION
Rituximab is generally considered safe for the treatment
of both malignant and nonmalignant diseases. Although
frequently used in women who are fertile, little is known
about the safety aspects during pregnancy. Since rituximab
is a chimeric antibody of the IgG isotype, it is likely to
cross the placental barrier, and one should consider the
risk of B-cell depletion in the child. To our knowledge, in
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vitro studies on placental transfer of rituximab have not
been reported, but rituximab levels could be demonstrated
in the exposed neonate. In our case, rituximab levels were
3.5 times lower in the neonate at birth when compared
to the serum concentrations of the mother. This is in
contrast with previously reported cases [15, 16] in which the
rituximab levels in the cord blood were higher compared
to maternal levels. As rituximab was administrated in the
second trimester in these cases, time of administration
during the pregnancy may contribute to this diﬀerence.
Maternal IgG is transferred across the placenta by means
of a specific receptor-mediated mechanism. Mother-to-fetus
IgG transfer starts at week 16 of gestation. After 22 weeks
of gestation, the fetal IgG levels increase rapidly [20]. Thus,
when rituximab exposure starts at gestational age 16 weeks,
as occurred in the two cases reported [15, 16], there has
been a maximum period of opportunity for transfer. In our
case, exposure was relatively short prior to birth. Although
most of IgG is acquired in the last 4 weeks of pregnancy,
the exposure may not have been long enough to reach
the levels previously reported. Despite the lower level of
rituximab in the cord blood, the number of neonatal B-
lymphocytes at birth was zero. This is similar to previous
reports [15, 16, 18, 19]. During follow-up, all children
showed an increase of B-lymphocytes to the age-specific
normal reference levels demonstrating the transient eﬀect of
rituximab (Table 1). Reconstitution of B-cells coincided with
the known half-life of rituximab. Although B-cell function
was initially impaired, the clinical outcome of all patients
was good. None of the patients had serious infection-related
complications. The explanation for this finding may be the
fact that in the first few months of life, the neonate largely
depends on maternal IgG for immunity, and B-cell function
still has to develop. The rituximab eﬀect may already be
diminished properly before the infant depends on its own B-
cell function. The data of adequate IgG and vaccination titres
are supportive of this.
Although the therapeutic benefit of rituximab in malig-
nancies is well established, its eﬃcacy in the treatment of
autoimmune diseases is still under investigation. Likewise,
the exact mechanism(s) by which the B-cell depletion pro-
moted by rituximab ameliorates autoimmune disease activ-
ity remains unclear. Despite lack of complete understanding
of how rituximab targets autoimmune diseases, the antibody
has been applied in the treatment of various ailments such
as rheumatoid arthritis (RA), Systemic Lupus Erythematosus
[21, 22], and ITP [12]. Early success with rituximab in ITP
has led to its widespread use and incorporation into recent
treatment schemes. A meta-analysis by Arnold et al. demon-
strated [23] that rituximab was associated with a platelet
count response defined as > 50 × 109 cells/L. However, none
of the identified studies included a control group and none
met all predetermined methodological quality criteria for
observational studies. The eﬃcacy of rituximab compared
with standard treatments for ITP could not be determined,
and the authors strongly urge for randomized controlled
trials.
In our case, rituximab administration did not result in
increased platelet count and rituximab was stopped and IVIG
treatment was started. This finding underlines the need for
additional data to determine the eﬀectiveness of rituximab
for ITP in pregnant women.
5. CONCLUSION
Intrauterine exposure to rituximab appears not to be harm-
ful to the neonate as neither in the literature nor in our
case any complications related to rituximab are reported.
However, data are limited to a handful of case reports,
and caution should be taken when considering rituximab
administration during pregnancy. In addition, rituximab
should not be used indiscriminately, but should be reserved
for carefully selected cases when first and second line therapy
fails. Further studies are warranted to fully evaluate the safety
of rituximab during pregnancy.
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